SCHEMBL19878466

SCHEMBL19878466

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(F)cc3)c(F)c2)ccn1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 7/20 0.72
ABL1 P00519 4/20 0.72
EPHX2 P34913 4/20 0.72
KDR P35968 4/20 0.72
RET P07949 4/20 0.72
MAPK14 Q16539 4/20 0.72
RIPK2 O43353 3/20 0.72
EPHA2 P29317 3/20 0.72
MAP3K20 Q9NYL2 3/20 0.72
BRAF P15056 3/20 0.72
DDR2 Q16832 3/20 0.72
ABCB11 O95342 2/20 0.72
HTR1A P08908 2/20 0.72
PDGFRB P09619 2/20 0.72
ADORA3 P0DMS8 2/20 0.72
KIT P10721 2/20 0.72
FGFR1 P11362 2/20 0.72
PDGFRA P16234 2/20 0.72
FLT1 P17948 2/20 0.72
MAOA P21397 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19888870 0.95 RAF1 (0.68) RAF1ABL1EPHX2KDRRET
SCHEMBL14911164 0.92 ABL1 (0.73) RAF1ABL1EPHX2KDRRET
SCHEMBL19888727 0.92 RAF1 (0.75) RAF1ABL1EPHX2KDRRET
SCHEMBL19888732 0.92 RIPK2 (0.70) RAF1ABL1EPHX2KDRRET
SCHEMBL19888730 0.91 RAF1 (0.78) RAF1ABL1EPHX2KDRRET
SCHEMBL15367107 0.90 RAF1 (0.68) RAF1ABL1EPHX2KDRRET
SCHEMBL18191221 0.90 RAF1 (0.76) RAF1ABL1EPHX2KDRRET
SCHEMBL19888733 0.90 ABL1 (0.65) RAF1ABL1EPHX2KDRRET
SCHEMBL19888742 0.89 KDR (0.69) RAF1ABL1EPHX2KDRRET
SCHEMBL10105558 0.89 KDR (0.71) RAF1ABL1EPHX2KDRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3500257-B1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2025-07-02 EP disclosed
US-11066370-B2 Kinase inhibitor compounds, compositions, and methods of treating cancer ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-07-20 US disclosed
US-11066370-B2 Kinase inhibitor compounds, compositions, and methods of treating cancer ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-07-20 US disclosed
US-20200325103-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2020-10-15 US disclosed
US-20200325103-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2020-10-15 US disclosed
US-10519113-B2 Kinase inhibitor compounds, compositions, and methods of treating cancer ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2019-12-31 US disclosed
US-10519113-B2 Kinase inhibitor compounds, compositions, and methods of treating cancer ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2019-12-31 US disclosed
US-20190202789-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) 2019-07-04 US disclosed
US-20190202789-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) 2019-07-04 US disclosed
EP-3500257-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER Icahn School of Medicine at Mount Sinai (US) 2019-06-26 EP disclosed
WO-2018035346-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) 2018-02-22 WO disclosed
WO-2018035346-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) 2018-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200325103-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER MAP3K1, KSR1, MAP3K11 RAF1 16/4885ABL1 38/4885EPHX2 2634/4885
US-10519113-B2 Kinase inhibitor compounds, compositions, and methods of treating cancer MAP3K1, KSR1, MAP3K11 RAF1 16/4885ABL1 38/4885EPHX2 2634/4885
US-11066370-B2 Kinase inhibitor compounds, compositions, and methods of treating cancer MAP3K1, KSR1, MAP3K11 RAF1 16/4885ABL1 38/4885EPHX2 2634/4885
US-20190202789-A1 KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER MAP3K1, KSR1, MAP3K11 RAF1 16/4885ABL1 38/4885EPHX2 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.